Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer

Table 3 Factors associated with progression-free survival

Characteristics	N	Univariate analysis			Multivariate analysis
Characteristics	N	HR	95% CI	P	Adjusted HR	95% CI	P
Age, years
<50	39	1 (Ref)	−	−	1 (Ref)	−	−
≥50	89	1.540	0.958−2.477	0.075	1.377	0.850−2.232	0.194
FIGO stage
III	77	1 (Ref)	−	−	1 (Ref)	−	−
IV	51	1.903	1.244−2.912	0.003	1.358	0.867−2.126	0.182
Primary treatment strategy
PDS	79	1 (Ref)	−	−	1 (Ref)	−	−
NAC	49	2.098	1.373−3.206	0.001	2.103	1.321−3.348	0.002
Residual tumor after PDS/IDS
Optimal debulking	109	1 (Ref)	−	−	1 (Ref)	−	−
Suboptimal debulking	19	1.515	0.867−2.648	0.145	1.587	0.879−2.865	0.126
BRCA status
Wild-type	77	1 (Ref)	−	−	1 (Ref)	−	−
Mutation	51	0.484	0.310−0.755	0.001	0.502	0.318−0.795	0.003

Abbreviations: CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC neoadjuvant chemotherapy, IDS interval debulking surgery, HR hazard ratio, CI confidence interval, Ref reference

ISSN: 1757-2215